Oregon 2023 Regular Session

Oregon Senate Bill SB192

Introduced
1/9/23  
Refer
1/13/23  
Report Pass
4/5/23  
Report Pass
5/4/23  
Engrossed
6/20/23  
Refer
6/20/23  
Report Pass
6/22/23  
Enrolled
6/22/23  
Passed
7/27/23  
Chaptered
8/3/23  

Caption

Relating to prescription drugs; and prescribing an effective date.

Impact

The implementation of SB 192 is expected to significantly impact state laws regarding pharmacy practices and the healthcare delivery system. By establishing a more structured approach to drug prescribing and dispensing, the bill aims to prevent over-prescribing and abuse of prescription medications. This could also lead to more transparent pricing mechanisms for medications, ultimately benefiting patients who often face high costs. The anticipated outcomes include improved public health and reduced healthcare disparities due to better management of prescription drug access.

Summary

Senate Bill 192 addresses the regulation of prescription drugs and aims to enhance the healthcare framework within the state. The bill specifies new guidelines for the prescribing, dispensing, and management of prescription medications. It emphasizes the importance of ensuring patient safety and improving access to necessary drugs, while it also seeks to control drug pricing through stricter oversight measures. Supporters believe that these regulations will lead to better healthcare outcomes by promoting responsible prescribing practices among healthcare providers.

Sentiment

The sentiment around SB 192 has been largely positive among healthcare advocates and professionals. Many argue that the bill is a step in the right direction toward safeguarding public health and enhancing the integrity of prescribing practices. However, some concerns have been raised by opponents who fear that overly restrictive measures may limit access to necessary medications for patients. This polarized sentiment underscores the ongoing debate about balancing regulation with patient access to care.

Contention

Key points of contention regarding SB 192 include the balance between regulation and access to prescription drugs. Critics have expressed worries that certain provisions in the bill could lead to cumbersome restrictions for both healthcare providers and patients. They argue that while the intention to safeguard against drug misuse is commendable, it is crucial not to hinder patients' timely access to necessary medications. This highlights the challenges of creating effective legislation that protects patients while maintaining availability of essential healthcare resources.

Companion Bills

No companion bills found.

Previously Filed As

OR SB404

Relating to prescription drugs; prescribing an effective date.

OR HB2057

Relating to prescription drugs; prescribing an effective date.

OR SB289

Relating to prescription drugs.

OR HB3223

Relating to prescription drugs; prescribing an effective date.

OR HB2599

Relating to the Prescription Drug Affordability Board; prescribing an effective date.

OR HB3444

Relating to health care; prescribing an effective date.

OR HB3258

Relating to prescription drug monitoring; and prescribing an effective date.

OR HB2630

Relating to exemption of prescription drug sales; prescribing an effective date.

OR SB61

Relating to exemption of prescription drug sales; prescribing an effective date.

OR SB716

Relating to off-label indications for prescription drugs; prescribing an effective date.

Similar Bills

MS SB2715

Pharmaceuticals; authorize the Division of Medicaid to establish a wholesale prescription drug importation program.

MS SB2733

Pharmaceuticals; authorize the Division of Medicaid to establish a wholesale prescription drug importation program.

CT HB05384

An Act Concerning Prescription Drug Costs.

OR SB404

Relating to prescription drugs; prescribing an effective date.

MS SB2012

Mississippi Health Care Cost Transparency Act; enact.

LA HB616

Provides for disclosure of prescription drug cost information

FL H1183

Prescription Drug Price Transparency

MN HF3054

Prescription drug transparency provisions modified.